Introduction
osteoporosis (oP) is a major health concern in many industrialized countries with a continuously increasing number of yearly established osteoporotic fractures (9) . Bone mineral density (BMD), an accurate and precise measure of bone mass, has been identified as one of the main factors determining bone strength and fracture risk. Other factors influencing the bone characteristics include bone microarchitecture, bone microdamage, mineralization and turnover (12, 16) .
the standard measurement of BMD is performed with the method of dual-energy X-ray absorptiometry (DXA) and represents a reference standard for the diagnosis of osteoporosis (20) . the trabecular bone score (tBS) is a new texture measurement that can be applied to DXA images and can be used for differentiation and correlation between various characteristics of bone microarchitecture. tBS is a new index defined on the basis of DXA measurement of lumbar spine and showing correlation between 3D parameters of the trabecular bone microarchitecture and the fracture risk, independently of the BMD. there is an established model that allows the interpretation of the relationship between tBS and other bone microarchitecture parameters. Higher scores reflect stronger and fracture-resistant microarchitecture, whereas lower scores indicate bone that is weaker and more susceptible to fracture (7) .
Receptor activator of nuclear factor-κB ligand (RANKL) is a protein binding to RAnK on the osteoblasts' surface and is the main mediator of their differentiation, activation and survival (2) . in postmenopausal osteoporosis (PMo), RAnKl is directly associated with osteoclast-mediated bone resorption (5, 11) . osteoprotegerin binds to RAnKl and is involved in the regulation of the RAnK-RAnKl pathway (17) .
Denosumab is a fully human monoclonal antibody that binds with high affinity and specificity to RANKL, mimicking the effect of endogenous osteoprotegerin and thus, inhibiting the interaction between RAnK and its ligand RAnKl. in this manner, denosumab effectively inhibits bone resorption and may rapidly increase the BMD and reduce the risk of osteoporotic fractures (1, 4, 14) . Denosumab (Prolia) is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Prolia significantly reduces the risk of vertebral, non-vertebral and hip fractures (6) . 
EFFICACY OF DENOSUMAB FOR CONTROL OF BONE MINERAL DENSITY AND MICROARCHITECTURE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: A ONE-YEAR EXPERIENCE

Materials and Methods
Subjects the study was conducted at the Rheumatology clinic of the Medical University of Sofia in Bulgaria, in accordance with good clinical practice and the principles of the Declaration of helsinki. the institutional Review Board at the clinic approved the study protocol. All participating patients provided written informed consent.
All patients (n = 36), postmenopausal women diagnosed with oP who had a BMD score lower than -2.5 both at lumbar spine and total hip¸ were treated with 60 mg denosumab subcutaneously once per 6 months. Supplementation with ca and vitamin D was either initiated or continued. none of the subjects had previously received corticosteroid treatment. Fourteen percent of the patients had concomitant rheumatic disease; and 2.8 %, endocrine disease. Sixty-one percent of the enrolled subjects had been previously treated for osteoporosis. Patients who had experienced previous osteoporotic fracture (either wrist, lumbar or proximal femur) represented 25 % of the examined population ( Table 1) .
DXA BMD and TBS assessments
For all patients, BMD assessments were performed at baseline and at 12 months for the lumbar spine and total hip. BMD was measured by a lunar Prodigy ® Primo osteodensitometer (Ge healthcare, caserta, italy). A new software program (tBS insight ® v1.9, Med-imaps, Pessac, France) was applied to the standard lumbar spine DXA scans to determine their tBS indexes. lumbar spine scans included l1 to l4 vertebrae. the scanner precision (precision error), together with the quality and reliability of individual scans were measured using the LSC (least significant change) calculation. The precision error measured for the osteodensitometer used in the present work is: 0.015 g/cm 2 for PA spine (lSc of 0.042 g/cm 2 ) and 0.008 g/cm 2 for femoral neck (lSc of 0.022 g/cm 2 ), which is close to the minimum acceptable precision for an individual technologist (18) .
FRAX measurement and fracture risk assessment the fracture risk was assessed for all patients (n = 36) with the online FRAX ® tool (Who Fracture Risk Assessment tool, http://www.shef.ac.uk/FRAX/tool.jsp). At baseline, the estimated risk of major osteoporotic fracture and for hip fracture was 6.12 % and 1.8 %, respectively. (Fig. 1 to Fig. 6 ).
Results and Discussion
Changes of BMD and T-score of lumbar spine from baseline to month 12 in recent years, there is a great amount of information about the correlation between fracture risk and various bone parameters. BMD is one of the major factors and as such is continuously used for representing the change in bone mass in response to different drugs. Denosumab increased the BMD at the lumbar spine (p = 0.2) at month 12 compared with the baseline values in 88.9 % of all patients. A change of 3.9 % in BMD favoring denosumab treatment was measured at the end of the observation (Fig. 1) . in correlation with the increase of BMD at the lumbar spine, the t-score improved in 94.4 % of the patients, resulting in a significant change of 13.8 % compared to the baseline T-score mean value (p < 0.05) (Fig. 2) .
Changes of BMD and T-score of total hip from baseline to month 12 Seventy-five percent (n = 27) of all denosumab-treated patients showed an increase in the BMD at the total hip at month 12. there was a 1.3 % increase in the BMD at the end of the observation in comparison with the mean baseline values (p = 0.2) (Fig. 3) . Similarly to the results related to the t-score change at the lumbar spine, the t-score of total hip also changed in corresponding proportion to the increase of BMD. There was a significant positive change of 4.5 % in the total hip t-score, determined in 72 % of the patients as compared with their baseline t-score values (p < 0.05) (Fig. 4).   Fig. 3 . effect of denosumab on BMD at the total hip. Fig. 4 . change in t-score of total hip.
Change in TBS the assessment of bone microarchitecture already has a real practical application in the evaluation of any treatment effect. TBS is a new method reflecting the status of bone microarchitecture.
treatment with denosumab of osteoporotic postmenopausal women for a period of 12 months led to an increase in tBS by 1.7 %. For the one-year treatment period, this increase (p = 0.1) was observed in 69.4 % of all patients (Fig. 5) . Fracture risk reduction in response to denosumab treatment at month 12 We did not observe clinically manifested fractures during the evaluation period.
the fracture risk reduction was measured using the online FRAX ® tool (see materials and methods). in comparison to the baseline values which demonstrated fracture risk of 6.12 % for major osteoporotic fractures and 1.8 % for hip fractures, the one-year treatment with denosumab resulted in a risk reduction of 13.3 % for major oP fractures and 38.4 % for hip fractures, respectively (Fig. 6) .
Safety
Denosumab was well tolerated by all patients with no serious adverse reactions reported. The safety profile of the drug was in a complete correlation with that included in its summary of Product characteristics (SmPc) (6, 17) . only one case of herpes zoster infection and one patient with a local reaction in the injection spot were documented during the treatment period of 12 months. no patients discontinued denosumab treatment due to safety reasons.
in our work, the variance in tBS was largely unrelated to BMD at baseline and throughout the treatment period, supporting the concept that tBS provides distinct information, independent of BMD and in correlation with the results reported by hans et al. (8) . these results, coupled with the observation that TBS influences fracture risk, suggest that this novel technique may have a role in managing patients with oP and warrants further investigation. the 3.9 % increase in BMD at the lumbar spine and the 1.3 % at the total hip correlated with a decrease in the major fracture risk by 13.3 % and 38.4 % for hip fractures, respectively. the combination of different approaches, such as tBS, t-score, FRAX ® , etc. would create a more complete picture of the effect of particular treatment, progression of oP, fracture risk status, etc.
Due to its unique mode of action, denosumab represents a new type of pathophysiological treatment, mimicking the natural process occurring in the normal bone. in this respect, denosumab has the potential to restore the natural process and balance of bone creation and destruction, rather than changing it as bisphosphonates do.
Although our results on the effect of denosumab on BMD change appeared to be insignificant, there was a clear tendency towards an increase in BMD and tBS (Fig. 1, Fig. 3, Fig. 5 ), which are two independent factors for treatment assessment. however, this was only a 12-month treatment and the patient population was not large enough in order to look for statistical significance. Despite all these limitations of our study, we found a clear positive effect of denosumab treatment. these results are in accordance with the already published data on denosumab efficacy in increasing BMD in comparison to placebo and bisphosphonates (3, 10, 13, 15) . in regards to the adverse events, denosumab was well tolerated by all patients with no serious adverse events, which is in full correlation with its SmPc and previously reported data (6, 17, 19) .
All patients that have been treated with denosumab for 12 months and whose results are reported herein will continue their oP therapy with this new medication with a unique mode of action and more data on its efficacy and safety will be additionally analyzed and further presented.
Conclusions
Denosumab was highly effective in the 12-month treatment of postmenopausal women with oP, leading to an increase of BMD at lumbar spine and total hip, tBS and FRAX ® . Also, this novel molecule showed a favorable safety profile and was well tolerated by all patients with no need for treatment discontinuation. our results clearly demonstrate that denosumab deserves a valuable place in the current treatment of oP.
